Mood Stabilizers: Lithium, Valproate, Lamotrigine and Bipolar Disorder Safety

Educational pharmacology review updated 10 November 2026. This information does not replace a patient-specific clinical evaluation or current local prescribing guidance. Overview Mood-stabilizing medicines prevent or manage manic, depressive and recurrent episodes in bipolar disorder, but their efficacy differs by episode polarity. Lithium remains a major maintenance option, while certain antipsychotics and anticonvulsants have phase-specific…

Read Full News

Antidepressants: SSRIs, SNRIs, TCAs, MAOIs, Clinical Use and Tapering

Educational pharmacology review updated 10 November 2026. This information does not replace a patient-specific clinical evaluation or current local prescribing guidance. Introduction Antidepressants are used for major depressive disorder and selected anxiety, obsessive-compulsive, pain and other conditions. Choice should incorporate symptom severity, patient preference, prior response, comorbidity, interacting medicines, pregnancy considerations and access to evidence-based…

Read Full News

Antipsychotic Drugs: Receptor Pharmacology, Schizophrenia Treatment and Clozapine Safety

Educational pharmacology review updated 10 November 2026. This information does not replace a patient-specific clinical evaluation or current local prescribing guidance. Overview Antipsychotics reduce psychotic symptoms in schizophrenia and are also used for specific bipolar disorder and other indications. Choice requires balancing symptom control with movement disorders, metabolic and cardiovascular risks, prior response and patient…

Read Full News

Antiseizure Medications: Mechanisms, Epilepsy Syndromes, Pregnancy and Monitoring

Medical education review updated 10 November 2026. Information is educational; treatment requires individualized clinical assessment and locally approved products. Overview Antiseizure medications (ASMs) reduce seizure recurrence through modulation of neuronal excitability or synaptic transmission. A drug that treats focal seizures may worsen some generalized epilepsies, so selection begins with seizure type, epilepsy syndrome, age, comorbidities,…

Read Full News

Barbiturates: GABA-A Pharmacology, Clinical Uses and Overdose Risks

Medical education review updated 10 November 2026. Information is educational; treatment requires individualized clinical assessment and locally approved products. Overview Barbiturates are sedative-hypnotic agents that potentiate inhibitory GABA neurotransmission. Clinical use has declined because of a narrow therapeutic index, respiratory suppression, enzyme induction and dependence. Phenobarbital remains useful for selected epilepsy indications and medically supervised…

Read Full News

Benzodiazepines: GABA-A Mechanism, Clinical Indications, Dependence and Tapering

Medical education review updated 10 November 2026. Information is educational; treatment requires individualized clinical assessment and locally approved products. Overview Benzodiazepines are positive allosteric modulators at GABA-A receptors with anxiolytic, anticonvulsant, sedative, muscle-relaxant and amnestic properties. They can be valuable for acute indications, but routine prolonged use for anxiety or insomnia raises risks of tolerance,…

Read Full News

Sedative-Hypnotics: Insomnia Pharmacology, CBT-I and Medication Safety

Medical education review updated 10 November 2026. Information is educational; treatment requires individualized clinical assessment and locally approved products. Overview Sedative-hypnotic drugs decrease wakefulness or promote sleep, but chronic insomnia should first be evaluated for medical, psychiatric, circadian and sleep-related breathing contributors. Cognitive behavioral therapy for insomnia (CBT-I) is recommended as first-line management. Medication selection,…

Read Full News

Myasthenia Gravis Drugs: Pyridostigmine, Immunotherapy and New Targeted Treatments

Medical education review updated 10 November 2026. Information is educational; treatment requires individualized clinical assessment and locally approved products. Overview Myasthenia gravis (MG) is an autoimmune disorder of neuromuscular transmission, most commonly involving acetylcholine receptor (AChR) or muscle-specific kinase (MuSK) antibodies. Weakness worsens with repeated activity and improves with rest, but respiratory or bulbar deterioration…

Read Full News

Glaucoma Drugs: Aqueous Humor Pharmacology, Modern First-Line Therapy and Safety

Scientific educational review. Updated 10 November 2026. Clinical treatment must follow patient-specific assessment and locally approved prescribing information. Overview Glaucoma is a group of progressive optic neuropathies leading to retinal ganglion-cell loss and visual-field damage. Raised intraocular pressure (IOP) is a modifiable risk factor, but normal-tension glaucoma also occurs. Therapy targets a personalized IOP reduction…

Read Full News

Ganglionic Blockers: Nicotinic Nn Receptors, Autonomic Effects and Historical Use

Scientific educational review. Updated 10 November 2026. Clinical treatment must follow patient-specific assessment and locally approved prescribing information. Overview Ganglionic blockers inhibit neurotransmission at autonomic ganglia by blocking neuronal nicotinic acetylcholine receptors (Nn). Once used in hypertension and controlled hypotension, these drugs now have virtually no routine clinical role because they indiscriminately impair sympathetic and…

Read Full News